Table 2.
Differences of demographic, clinical and laboratory characteristics between IgG4-RD patients complicated with AR/CRS (case group) and without AR/CRS (control group).
| Characteristics | ALL (n = 756) | Case group (n = 408)a | Control group (n = 348)a | P- valueb |
|---|---|---|---|---|
| Demographics | ||||
| Age at disease onset, years, median (IQRc) | 56 (46–63) | 56 (46–62) | 56 (46–64) | 0.4380 |
| Age at diagnosis, years, median (IQR) | 57.5 (49–65) | 57.5 (50–64) | 58 (48–65) | 0.5078 |
| Time from onset to diagnosis, months, median (IQR) | 24 (12–48) | 24 (12–60) | 12 (6–36) | 0.0089* |
| Follow-up period, months, median (IQR) | 48 (26–71.5) | 51.5 (33–72) | 41 (24–70) | 0.0107* |
| Disease duration, months, median (IQR) | 24 (12–48) | 24 (12–60) | 12 (6–36) | 0.0096* |
| Gender (Male: Female) | 1.39:1 | 1.34:1 | 1.46:1 | 0.6838 |
| Clinical features n (%) | ||||
| Other types of allergic disease | 341 (45.11) | 216 (52.55) | 125(36.23) | < 0.0001* |
| Number of involved organs ≥ 3 | 391 (51.7) | 269 (65.5) | 122(35.4) | < 0.0001* |
| Lymph node | 262 (34.66) | 169 (41.12) | 93 (26.96) | < 0.0001* |
| Thyroid gland | 46 (6.08) | 30 (7.30) | 16 (4.64) | 0.1273 |
| Lung | 174 (23.02) | 123 (29.93) | 51 (14.78) | < 0.0001* |
| Kidney | 113 (14.95) | 64 (15.57) | 49 (14.20) | 0.5590 |
| Liver | 28 (3.70) | 17 (4.14) | 11 (3.19) | 0.4919 |
| Pancreas | 217 (28.70) | 122 (29.68) | 95 (27.54) | 0.5156 |
| Biliary system | 96 (12.70) | 52 (12.65) | 44 (12.75) | 0.9667 |
| Gallbladder | 67 (8.86) | 43 (10.46) | 24 (6.96) | 0.0911 |
| Retroperitoneal fibrosis | 124 (16.40) | 61 (14.84) | 63 (18.26) | 0.1020 |
| Mesentery | 7 (0.93) | 4 (0.97) | 3 (0.87) | 0.8822 |
| Aorta | 17 (2.25) | 13 (3.16) | 4 (1.16) | 0.0642 |
| Prostate | 35 (4.63) | 20 (4.87) | 15 (4.35) | 0.7355 |
| Salivary gland | 406 (53.70) | 260 (63.26) | 146 (42.32) | < 0.0001* |
| Lacrimal gland | 300 (39.68) | 214 (52.07) | 86 (24.93) | < 0.0001* |
| Parotid gland | 212 (28.04) | 146 (35.52) | 66 (19.13) | < 0.0001* |
| Laboratory findings | ||||
| Serum IgG4 (mg/dL), median (IQR) | 502 (248–1360) | 650 (312–1520) | 385 (185–1136) | < 0.0001* |
| Serum IgG4 (mg/dL)/IgG (mg/dL), median (IQR) | 0.28 (0.14–0.49) | 0.32 (0.19–0.53) | 0.21 (0.12–0.38) | < 0.0001* |
| Serum IgE (IU/ml), median (IQR) | 246 (72–655) | 347 (153–958) | 98 (39–288) | < 0.0001* |
| CRP (mg/dl), median (IQR) | 1.83 (0.68–6.40) | 1.98 (0.74–6.87) | 1.63 (0.61–6) | 0.5607 |
| ESR (mm/h), median (IQR) | 13 (7–36) | 14 (7–42) | 12 (6–28) | 0.0481* |
| Elevated CRP, n (%) | 117 (15.48) | 67 (16.30) | 50 (14.50) | 0.4934 |
| Elevated ESR, n (%) | 228 (30.16) | 142 (34.55) | 86 (24.93) | 0.0041* |
| Eosinophilia, n (%) | 92 (12.17) | 73 (17.76) | 19 (5.51) | < 0.0001* |
| C3 (g/L) mean (SD) | 0.89 (0.74–1.08) | 0.84 (0.73–1.04) | 0.97 (0.81–1.12) | < 0.0001* |
| C4 (g/L), median (IQR) | 0.19 (0.15–0.26) | 0.19 (0.14–0.24) | 0.21 (0.16–0.28) | < 0.0001* |
| ANA (+), n (%) | 94 (12.43) | 51 (12.41) | 43 (12.46) | 0.9818 |
| RF (+), n (%) | 97 (12.83) | 56 (13.63) | 41 (11.88) | 0.4758 |
| Hypocomplementemia, n (%) | 232 (30.69) | 160 (38.93) | 72 (20.87) | < 0.0001* |
aCase group included IgG4-RD patients complicated with AR or CRS, and the control group included IgG4-RD patients without AR or CRS; b*means P-value < 0.05; cIQR, interquartile range